CCND1 and Thrombocytopenia: On the other hand, a significantly higher risk of non-response after the 6th cycle of therapy was observed in patients with thrombocytopenia (OR = 9.22), those with the presence of 17p/TP53 deletion (OR = 12.46) and those with the presence of t(11.14)/CCND1 translocation (OR = 55.20).